|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 507.56 USD | +5.30% |
|
-5.80% | -12.84% |
| 07-30 | Madrigal Pharmaceuticals Q2 Loss Widens, Revenue Increases | MT |
| 07-30 | Madrigal Pharmaceuticals, Inc., Q2 2026 Earnings Call, Jul 30, 2026 |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Neutral | Neutral |
| Resistance | 514.39 | 565.4 | 598.91 |
| Spread/Res. | -1.33% | -10.23% | -15.25% |
| Spread/Supp. | +8.61% | +19.19% | +21.16% |
| Support | 467.32 | 425.85 | 418.9 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- MDGL Stock
- Charts Madrigal Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
